Business context and reporting period
Aethlon Medical, Inc. is a development-stage medical-device company developing its ADAPT platform, including the Hemopurifier for infectious disease and cancer applications, and a device intended to reduce sepsis. This Form 10-K reports the fiscal year ended March 31, 2012—not calendar 2011 or a standalone fourth quarter. The company began recognizing revenue under a DARPA contract during the year and reported that it had emerged from the development stage.
Key financial metrics
| Metric | FY ended Mar. 31, 2012 | FY ended Mar. 31, 2011 |
|---|---|---|
| Revenue | $1,359,621 | $0 |
| Operating expenses | $4,473,956 | $4,557,116 |
| Operating loss | $3,114,335 | $4,557,116 |
| Net loss | $8,111,340 | $5,711,435 |
| Net cash used in operating activities | $1,841,355 | $1,968,333 |
| Cash at year-end | $143,907 | $15,704 |
Revenue consisted primarily of $1,358,189 from DARPA milestone work; product sales were $1,432. The filing does not provide a meaningful gross-margin figure. R&D expense was approximately $1.089 million, versus $440,000 in FY2011. Other expense totaled $4,997,005, including $3,793,758 of interest and other debt expense and a $766,903 loss from changes in derivative-liability fair value.
Material changes versus the prior period
- Revenue rose from zero as the company began the DARPA-funded sepsis-device program; five of eight first-year milestones were achieved by year-end.
- Operating expenses declined 1.8%, mainly because payroll and stock-compensation expense fell, partly offset by higher scientific consulting, professional fees, and DARPA-related costs.
- Net loss increased by $2.4 million. A major driver was the swing in derivative fair-value results—from a $6.080 million gain in FY2011 to a $766,903 loss in FY2012—alongside other changes in debt-related expenses.
- Shares outstanding increased from 77.5 million to 117.5 million during the fiscal year. The company issued 28.9 million shares to convert approximately $2.06 million of debt and accrued interest.
Liquidity, debt, and outlook
At March 31, 2012, current assets were $696,036 and current liabilities were $10,134,315, producing a $9,438,279 working-capital deficit. Total assets were $838,694, against a stockholders’ deficit of $9,295,621. The balance sheet included $3,005,473 of convertible notes payable net of discounts, $654,796 of notes payable, and $3,588,615 of derivative liabilities. The filing identifies substantial overdue debt; it also states that $1,524,710 of promissory notes were overdue. The auditor’s report highlights defaults, recurring losses, negative working capital, and substantial doubt about the company’s ability to continue as a going concern.
Management said additional financing would be required and that operating revenue was not expected to meet near-term funding needs. It reported raising $792,000 through private transactions and collecting $400,114 under the DARPA contract after year-end through June 28, 2012, but stated these funds were insufficient for the next 12 months. The DARPA award has potential payments of approximately $6.8 million over five years, but only the first-year contract was effective; later years require DARPA to exercise options. First-year payments were contingent on milestones, and the fixed-price structure exposes the company to cost overruns.
Management commentary, development, and risks
- Hemopurifier: The company reported nine patients treated in its India HCV study without device-related adverse events. Seven had more than 90 days of follow-up and were reported to have undetectable viral loads; three had more than 48 weeks of monitoring. These are early company-reported results from a small study and are not evidence of FDA approval or established efficacy. Management planned to resubmit an FDA investigational device exemption and pursue potential commercialization in India.
- Other programs: The company described preclinical capture data for viral and cancer-related targets and plans to license or sell its ELLSA research diagnostic tools. These programs remain subject to clinical, regulatory, commercial, and financing risks.
- Regulation and operations: The Hemopurifier had not received FDA marketing approval. Clinical outcomes, regulatory clearance, manufacturing scale-up, market acceptance, and patent protection are uncertain. The company had nine full-time employees as of June 2012.
- Capital and shareholder risks: The company depends on external financing, has significant defaulted or near-term-maturity debt, and may issue substantial additional shares. Convertible notes, warrants, and options create potential dilution. The filing also reports a DTC trading “chill,” thin trading, and penny-stock risks.
- Controls and legal matters: Management found disclosure controls and internal control over financial reporting ineffective due to material weaknesses in segregation of duties and accounting staffing. A Gemini lawsuit seeking damages and shares was dismissed without prejudice in June 2012; Gemini indicated it might refile. The company also had $437,800 accrued for potential registration-related liquidated damages.
Important facts for investors to verify
- Current cash, financing availability, debt defaults and maturities, and the status of management’s going-concern plans.
- Whether DARPA exercised later-year options, and whether milestones were accepted and paid without cost overruns.
- Full HCV study design, patient follow-up, adverse-event data, and regulatory status of the planned U.S. IDE submission and India commercialization.
- Subsequent share issuances, conversions, warrants, and potential dilution; reconcile share counts and financing disclosures through the latest filings.
- Remediation of the reported internal-control material weaknesses and the status of the Gemini dispute and accrued liquidated damages.